Hydroxychloroquine and Unexplained Recurrent Miscarriage
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Recurrent miscarriage affects women of childbearing age worldwide. Vascular endothelial
dysfunction and immunological impairment are associated with both recurrent miscarriage and
preeclampsia. To date, there is no effective or optimal therapeutic approach for these
conditions. Hydroxychloroquine has endothelial protective action via ant diabetic, lipid
lowering, antioxidant effects or direct endothelial protection. Hydroxychloroquine is an
antimalarial and immunomodulatory agent. In pregnancy, hydroxychloroquine is prescribed for
inflammatory conditions associated with adverse perinatal outcomes such as systemic lupus
erythematosus, antiphospholipid syndrome and placental inflammatory lesions such as chronic
histiocytic intervillositis, hydroxychloroquine has therapeutic potential to improve
placental function in pregnancies associated with heightened inflammation.